Difference between revisions of "Dosulepine-duloxetine"

From Psychiatrienet
Jump to: navigation, search
 
Line 3: Line 3:
 
| to = duloxetine
 
| to = duloxetine
 
| stop =  
 
| stop =  
{{stopDosulepine}}
+
{{TCAdecrease25p3d}}
| start =  
+
| start = {{StartAntidepressant}}
* '''Day 9:''' start administration of duloxetine in a normal dosage of 60 mg/day.
+
| info =
| info =  
+
* Safe target dose duloxetine = 60 mg
* {{theorSS}}
 
* Duloxetine is a inhibitor of CYP2D6, which metabolizes dosulepine.
 
 
}}
 
}}

Latest revision as of 11:11, 30 June 2023

dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin
Duloxetine
Type Antidepressant
Group SNRI
links
Medscape Duloxetine
PubChem 60835
PubMed Duloxetine
Kompas (Dutch) Duloxetine
Wikipedia Duloxetine

Switch medication from dosulepine to duloxetine.[1] [2]

Nietinrijdenbord.png Stop dosulepine
  • Day 1: Decrease with about 25% of the original dose per 3 days.
Eenrichtingbord.png Start duloxetine
  • Day 1: Start with 50% of the target dose
  • Day 8: Increase dose to 100% of the target dose
  • Day 9 and after: Gradually increase dose as necessary
Infobord.png More information
  • Safe target dose duloxetine = 60 mg
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.